Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H36N |
| Molecular Weight | 290.5065 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCC[N+]1=CC=C(C)C=C1
InChI
InChIKey=JDKRQGOIZPRQRU-UHFFFAOYSA-N
InChI=1S/C20H36N/c1-3-4-5-6-7-8-9-10-11-12-13-14-17-21-18-15-20(2)16-19-21/h15-16,18-19H,3-14,17H2,1-2H3/q+1
| Molecular Formula | C20H36N |
| Molecular Weight | 290.5065 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Hyaluronic acid biosynthesis Sources: https://www.ncbi.nlm.nih.gov/pubmed/3339273 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Depo-Medrol Approved UseINDICATIONS AND USAGE
Musculoskeletal Conditions. As with other adrenal steroids, DEPO-MEDROL Sterile
Aqueous Suspension has been found useful in alleviating the pain and lameness
associated with acute localized arthritic conditions and generalized arthritic conditions.
It has been used successfully to treat rheumatoid arthritis, traumatic arthritis, osteoarthritis,
periostitis, tendinitis, synovitis, tenosynovitis, bursitis, and myositis of horses;
traumatic arthritis, osteoarthritis, and generalized arthritic conditions of dogs. Allergic Conditions. This preparation is especially beneficial in relieving pruritus
and inflammation of allergic dermatitis, acute moist dermatitis, dry eczema, urticaria,
bronchial asthma, pollen sensitivities and otitis externa in dogs; allergic dermatitis and
moist and dry eczema in cats.Overwhelming Infections with Severe Toxicity. In dogs and cats moribund from
overwhelmingly severe infections for which antibacterial therapy is available (eg, critical
pneumonia, pyometritis), DEPO-MEDROL may be lifesaving, acting to inhibit the
inflammatory reaction, which itself may be lethal; preventing vascular collapse and
preserving the integrity of the blood vessels; modifying the patient’s reaction to drugs;
and preventing or reducing the exudative reaction which often complicates certain infections.
As supportive therapy, it improves the general attitude of the animal being
treated. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21018239
Curator's Comment: In rabbits intravitreal injection was used https://www.ncbi.nlm.nih.gov/pubmed/8505218
Rats: determinations of the minimum lethal
doses of myristyl-y-picolinium chloride (Miripirium) were made intravenously,
intraperitoneally, subcutaneously, and by stomach
tube. A lO-mg./ml. solution in physiological saline
was used intravenously and intraperitoneally.
A 30-mg/ml solution was used subcutaneously
and orally. The approximate LDw's
of myristyl-7-picolinium chloride are 200 mg/Kg
subcutaneously, 7.5 mg/Kg intraperitoneally,
30 mg/Kg intravenously, and 250 mg/Kg by
stomach tube.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:10:54 GMT 2025
by
admin
on
Mon Mar 31 22:10:54 GMT 2025
|
| Record UNII |
3ROK0LRZ8L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 524.1484B
Created by
admin on Mon Mar 31 22:10:54 GMT 2025 , Edited by admin on Mon Mar 31 22:10:54 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7631-49-4
Created by
admin on Mon Mar 31 22:10:54 GMT 2025 , Edited by admin on Mon Mar 31 22:10:54 GMT 2025
|
PRIMARY | |||
|
3ROK0LRZ8L
Created by
admin on Mon Mar 31 22:10:54 GMT 2025 , Edited by admin on Mon Mar 31 22:10:54 GMT 2025
|
PRIMARY | |||
|
DTXSID9048275
Created by
admin on Mon Mar 31 22:10:54 GMT 2025 , Edited by admin on Mon Mar 31 22:10:54 GMT 2025
|
PRIMARY | |||
|
1425941
Created by
admin on Mon Mar 31 22:10:54 GMT 2025 , Edited by admin on Mon Mar 31 22:10:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
17672
Created by
admin on Mon Mar 31 22:10:54 GMT 2025 , Edited by admin on Mon Mar 31 22:10:54 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |